Rexulti - Otsuka Pharmaceutical Co., Ltd.

WO2019121849A1 - Pharmaceutical tablet composition comprising brexpiprazole - Google Patents

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer's Dementia

Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders - Psychedelic Alpha

Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation

Manufacturers hope to expand labeling on schizophrenia therapy

Otsuka America Pharmaceutical 59148003813 - McKesson Medical-Surgical

Otsuka America Pharmaceutical 59148003613 - McKesson Medical-Surgical

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

REXULTI - Otsuka Pharmaceutical Co., Ltd. Trademark Registration

REXULTI® (brexpiprazole)